Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin.
Haemangioma is the most common tumour of endothelial origin, occurring in 4-10% of Caucasian infants. It is characterized by rapid growth during the first year of postnatal life, followed by spontaneous regression from 1 to 7 years of age. The cell surface adhesion molecule CD146 has been identified as an endothelial cell marker. Despite advances in understanding the functional role of CD146 in normal endothelial cells and tumour progression, its expression and a possible role in an endothelial tumour have not been studied. As part of an investigation of endothelial cell alterations in infantile haemangioma, differential expression studies were performed with several known antigens and endothelial cell markers. Using immunohistochemical and flow cytometric analyses, cultured human dermal microvascular endothelial cells isolated from newborn foreskin (HDMEC) were compared with endothelial cells derived from haemangioma tissue (HemECs). In addition, immunohistochemistry was used to compare haemangioma tissues with normal human skin. Unexpectedly, cultured HemECs showed a significantly lower level of CD146 than HDMECs by both flow cytometric analysis and immunofluorescence staining. Using immunohistochemical studies, it was further demonstrated that endothelia in all haemangioma tissues, regardless of the tumour phase, showed negative immunoreactivity for CD146. In contrast, strong positive staining for CD146 was observed in the pericyte-like cells that surround the endothelial layers. These findings are believed to be relevant to the molecular basis of haemangioma. Furthermore, it is possible that antibodies against CD146 may be useful for separating haemangioma-derived endothelial cells from normal endothelial cells and pericytes.
D015703:Antigens, CD; D015415:Biomarkers / Q000032:analysis; D051929:CD146 Antigen; D004730:Endothelium, Vascular / Q000276:immunology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D051272:Glucose Transporter Type 1; D006391:Hemangioma / Q000276:immunology*; D006801:Humans; D008562:Membrane Glycoproteins / Q000032:analysis*; D009004:Monosaccharide Transport Proteins / Q000032:analysis; D019006:Neural Cell Adhesion Molecules; D020286:Pericytes / Q000276:immunology; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis; D012878:Skin Neoplasms / Q000276:immunology*; D014407:Tumor Cells, Cultured
D015703:Antigens, CD; D015415:Biomarkers; D051929:CD146 Antigen; D051272:Glucose Transporter Type 1; C497902:MCAM protein, human; D008562:Membrane Glycoproteins; D009004:Monosaccharide Transport Proteins; D019006:Neural Cell Adhesion Molecules; D019408:Platelet Endothelial Cell Adhesion Molecule-1; C495677:SLC2A1 protein, human